# Theriva Biologics, Inc.: financial statements, quarterly

TOVX · NYSE · CIK 894158 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tovx.md) · [Financials](/companies/tovx/financials.md) · [Filings](/companies/tovx/filings.md) · [Insiders](/companies/tovx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tovx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.3](/filings/0001104659-26-055689.md) | [0.0 d](/filings/0001104659-26-093786.md) |
| Research and development | $m | [4.0](/filings/0001410578-24-001850.md) | [4.2 d](/filings/0001410578-25-000285.md) | [3.5](/filings/0001410578-25-001242.md) | [3.0](/filings/0001410578-25-001654.md) | [2.7](/filings/0001104659-25-109828.md) | [2.9 d](/filings/0001104659-26-026767.md) | [3.0](/filings/0001104659-26-055689.md) | [2.0](/filings/0001104659-26-093786.md) | [2.6](/filings/0001104659-25-109828.md) | [1.1 d](/filings/0001104659-26-026767.md) | [0.4](/filings/0001104659-26-055689.md) | [1.3](/filings/0001104659-26-093786.md) |
| Operating income | $m | [(4.2)](/filings/0001410578-24-001850.md) | [(6.2) d](/filings/0001410578-25-000285.md) | [(5.4)](/filings/0001410578-25-001242.md) | [(8.5)](/filings/0001410578-25-001654.md) | [(7.9)](/filings/0001104659-25-109828.md) | [(4.6) d](/filings/0001104659-26-026767.md) | [(4.4)](/filings/0001104659-26-055689.md) | [(13.1)](/filings/0001104659-26-093786.md) | [(4.4)](/filings/0001104659-25-109828.md) | [(2.1) d](/filings/0001104659-26-026767.md) | [(2.1)](/filings/0001104659-26-055689.md) | [(3.3)](/filings/0001104659-26-093786.md) |
| Income tax | $m | [(0.5)](/filings/0001410578-24-001850.md) | [(0.4) d](/filings/0001410578-25-000285.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(3.3)](/filings/0001410578-23-002348.md) | [(5.5) d](/filings/0001410578-24-000293.md) | [(5.2)](/filings/0001104659-25-109828.md) | [(8.3)](/filings/0001104659-25-109828.md) | [(7.7)](/filings/0001104659-25-109828.md) | [(4.4) d](/filings/0001104659-26-026767.md) | [(4.3)](/filings/0001104659-26-093786.md) | [(13.1)](/filings/0001104659-26-093786.md) | [(4.4)](/filings/0001104659-25-109828.md) | [(2.0) d](/filings/0001104659-26-026767.md) | [(2.0)](/filings/0001104659-26-093786.md) | [(3.2)](/filings/0001104659-26-093786.md) |
| Diluted EPS | $ per share | [(4.85)](/filings/0001410578-24-001850.md) | not reported | [(7.53)](/filings/0001410578-25-001242.md) | [(10.72)](/filings/0001410578-25-001654.md) | [(6.81)](/filings/0001104659-25-109828.md) | not reported | [(1.55)](/filings/0001104659-26-055689.md) | [(1.93)](/filings/0001104659-26-093786.md) | [(0.45)](/filings/0001104659-25-109828.md) | not reported | [(0.05)](/filings/0001104659-26-055689.md) | [(0.07)](/filings/0001104659-26-093786.md) |
| Basic EPS | $ per share | [(4.85)](/filings/0001410578-24-001850.md) | not reported | [(7.53)](/filings/0001410578-25-001242.md) | [(10.72)](/filings/0001410578-25-001654.md) | [(6.81)](/filings/0001104659-25-109828.md) | not reported | [(1.55)](/filings/0001104659-26-055689.md) | [(1.93)](/filings/0001104659-26-093786.md) | [(0.45)](/filings/0001104659-25-109828.md) | not reported | [(0.05)](/filings/0001104659-26-055689.md) | [(0.07)](/filings/0001104659-26-093786.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [31.2](/filings/0001410578-24-001850.md) | [23.2](/filings/0001410578-25-000285.md) | [18.3](/filings/0001410578-25-001242.md) | [16.6](/filings/0001410578-25-001654.md) | [16.4](/filings/0001104659-25-109828.md) | [11.6](/filings/0001104659-26-026767.md) | [10.0](/filings/0001104659-26-055689.md) | [12.1](/filings/0001104659-26-093786.md) | [7.5](/filings/0001104659-25-109828.md) | [13.1](/filings/0001104659-26-093786.md) | [14.4](/filings/0001104659-26-055689.md) | [11.3](/filings/0001104659-26-093786.md) |
| Current assets | $m | [34.8](/filings/0001410578-23-002348.md) | [27.4](/filings/0001410578-25-000285.md) | [21.7](/filings/0001410578-24-000601.md) | [19.7](/filings/0001410578-24-001342.md) | [19.5](/filings/0001410578-24-001850.md) | [16.3](/filings/0001104659-26-026767.md) | [12.5](/filings/0001410578-25-001242.md) | [14.7](/filings/0001410578-25-001654.md) | [9.9](/filings/0001104659-25-109828.md) | [17.5](/filings/0001104659-26-093786.md) | [16.8](/filings/0001104659-26-055689.md) | [13.7](/filings/0001104659-26-093786.md) |
| Total assets | $m | [61.5](/filings/0001410578-23-002348.md) | [55.2](/filings/0001410578-25-000285.md) | [48.7](/filings/0001410578-24-000601.md) | [42.4](/filings/0001410578-24-001342.md) | [40.1](/filings/0001410578-24-001850.md) | [35.4](/filings/0001104659-26-026767.md) | [32.2](/filings/0001410578-25-001242.md) | [35.8](/filings/0001410578-25-001654.md) | [30.8](/filings/0001104659-25-109828.md) | [38.2](/filings/0001104659-26-093786.md) | [38.2](/filings/0001104659-26-055689.md) | [34.9](/filings/0001104659-26-093786.md) |
| Current liabilities | $m | [8.7](/filings/0001410578-23-002348.md) | [6.7](/filings/0001410578-25-000285.md) | [6.0](/filings/0001410578-24-000601.md) | [6.8](/filings/0001410578-24-001342.md) | [7.3](/filings/0001410578-24-001850.md) | [7.6](/filings/0001104659-26-026767.md) | [8.1](/filings/0001410578-25-001242.md) | [12.4](/filings/0001410578-25-001654.md) | [11.0](/filings/0001104659-25-109828.md) | [10.0](/filings/0001104659-26-093786.md) | [10.3](/filings/0001104659-26-055689.md) | [12.1](/filings/0001104659-26-093786.md) |
| Total liabilities | $m | [17.7](/filings/0001410578-23-002348.md) | [15.5](/filings/0001410578-25-000285.md) | [14.6](/filings/0001410578-24-000601.md) | [14.7](/filings/0001410578-24-001342.md) | [15.5](/filings/0001410578-24-001850.md) | [16.3](/filings/0001104659-26-026767.md) | [16.7](/filings/0001410578-25-001242.md) | [25.2](/filings/0001410578-25-001654.md) | [24.1](/filings/0001104659-25-109828.md) | [22.9](/filings/0001104659-26-093786.md) | [22.8](/filings/0001104659-26-055689.md) | [22.7](/filings/0001104659-26-093786.md) |
| Long-term debt | $m | [0.2](/filings/0001410578-23-002348.md) | [0.2](/filings/0001410578-25-000285.md) | not reported | not reported | not reported | [0.1](/filings/0001104659-26-026767.md) | not reported | not reported | not reported | [1.7](/filings/0001104659-26-026767.md) | not reported | not reported |
| Short-term borrowings | $m | [0.1](/filings/0001410578-23-002348.md) | [0.1](/filings/0001410578-24-000293.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [41.2](/filings/0001410578-24-001850.md) | [37.0](/filings/0001104659-26-026767.md) | [31.4](/filings/0001104659-25-109828.md) | [25.9](/filings/0001104659-25-109828.md) | [24.6](/filings/0001104659-25-109828.md) | [19.1](/filings/0001104659-26-093786.md) | [15.5](/filings/0001104659-26-093786.md) | [10.6](/filings/0001104659-26-093786.md) | [6.7](/filings/0001104659-25-109828.md) | [15.4](/filings/0001104659-26-093786.md) | [15.4](/filings/0001104659-26-093786.md) | [12.2](/filings/0001104659-26-093786.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,953) d](/filings/0001410578-24-001850.md) | [(6,541) d](/filings/0001410578-25-000285.md) | [(4,881)](/filings/0001410578-25-001242.md) | [(3,452) d](/filings/0001410578-25-001654.md) | [(3,913) d](/filings/0001104659-25-109828.md) | [(4,691) d](/filings/0001104659-26-026767.md) | [(4,756)](/filings/0001104659-26-055689.md) | [(4,712) d](/filings/0001104659-26-093786.md) | [(4,319) d](/filings/0001104659-25-109828.md) | [(2,882) d](/filings/0001104659-26-026767.md) | [(2,456)](/filings/0001104659-26-055689.md) | [(3,085) d](/filings/0001104659-26-093786.md) |
| Capital expenditure | $k | [129 d](/filings/0001410578-24-001850.md) | [56.0 d](/filings/0001410578-25-000285.md) | not reported | not reported | [0.0 d](/filings/0001104659-25-109828.md) | [0.0 d](/filings/0001104659-26-026767.md) | not reported | not reported | [19.0 d](/filings/0001104659-25-109828.md) | [0.0 d](/filings/0001104659-26-026767.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [15.8](/filings/0001410578-23-002348.md) | [15.1](/filings/0001410578-24-000601.md) | [15.2](/filings/0001410578-24-001342.md) | [0.7](/filings/0001410578-24-001850.md) | [0.7](/filings/0001410578-25-001242.md) | [0.8](/filings/0001410578-25-001654.md) | [1.1](/filings/0001104659-25-109828.md) | [2.8](/filings/0001104659-26-055689.md) | [6.8](/filings/0001104659-26-093786.md) | [9.7](/filings/0001104659-25-109828.md) | [41.1](/filings/0001104659-26-055689.md) | [45.9](/filings/0001104659-26-093786.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 45,892,668 at 2026-08-07, from the cover of the [10-Q filed 2026-08-11](/filings/0001104659-26-093786.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.